NCATS Could Mitigate Pharma Valley of Death

Abstract

Genetic Engineering & Biotechnology NewsVol. 31, No. 10 Point of ViewNCATS Could Mitigate Pharma Valley of DeathNational Center for Advancing Translational Sciences Essential to Capitalize on Basic ResearchJohn C. Reed,John C. Reed,John C. Reed, M.D., Ph.D. (E-mail Address: jreed@sanfordburnham.org), is CEO, professor, and Donald Bren chief executive chair at the Sanford-Burnham Medical Research Institute in La Jolla, CA.Search for more papers by this authorPublished Online:1 Sep 2011https://doi.org/10.1089/gen.31.10.01AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byHow can attrition rates be reduced in cancer drug discovery?4 February 2013 | Expert Opinion on Drug Discovery, Vol. 8, No. 4The Valley of Death in anticancer drug development: a reassessmentTrends in Pharmacological Sciences, Vol. 33, No. 4Penicillin: the medicine with the greatest impact on therapeutic outcomes2 October 2011 | Applied Microbiology and Biotechnology, Vol. 92, No. 4 Volume 31Issue 10May 2011 Information© 2011 by GEN PublishingTo cite this article:John C. Reed,.NCATS Could Mitigate Pharma Valley of Death.Genetic Engineering & Biotechnology News.May 2011.6-8.http://doi.org/10.1089/gen.31.10.01Published in Volume: 31 Issue 10: September 1, 2011PDF download